Audax-backed AltaSciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early-stage drug development, completed its acquisition of Alliance Contract Pharma, a biotechnology-related research firm. Financial terms were not disclosed. “The addition of Alliance Contract Pharma continues to fulfill our strategy of creating a comprehensive offering that facilitates the outsourcing experience for our clients. We remain committed to providing our clients with value-added services that create a new paradigm of drug development outsourcing,” Chris Perkin, Altasciences CEO.